71027-13-9

Usage

Uses

Antidepressant.

InChI:InChI=1/C16H22Cl2N2O/c1-4-16(21)20(11-8-9-12(17)13(18)10-11)15-7-5-6-14(15)19(2)3/h8-10,14-15H,4-7H2,1-3H3/t14-,15-/m1/s1

Upstream product

• 95-76-1 m,p-dichloroaniline 
• 87014-71-9 (±)-trans-2-(dimethylamino)cyclopentanol 
• 285-67-6 Cyclopentene oxide 
• 67440-15-7 N-(trans-2-hydroxycyclopentyl)-N-(3,4-dichlorophenyl)propanamide 
• 67451-00-7 N-(2-oxocyclopentyl)-N-(3,4-dichlorophenyl)propanamide 
• 124-40-3 dimethyl amine 
• 123-62-6 propionic acid anhydride 

Relevant academic research and scientific papers

A new nontricyclic antidepressant agent. Synthesis and activity of N-[trans-2-(dimethylamino)cyclopentyl]-N-(3,4-dichlorphenyl)propanamide and related compounds

A series of new nontricyclic antidepressant compounds was synthesized. A representative of this class is shown. Five structural parameters were investigated: ring size, cis/trans stereochemistry, amide substitution, aromatic substitution, and amine substi

N-(2-Aminocyclopentyl)acylanilides and treating depression

N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula STR1 e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depresssant properties. Many of them are new. These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.

N-(2-aminocyclopentyl)alkanoylanilides

N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula STR1 e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depressant properties. Many of them are new. These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.